Literature DB >> 31571801

A Brave New World.

Kang-Ling Wang1,2, Chern-En Chiang1,2.   

Abstract

Year:  2019        PMID： 31571801      PMCID： PMC6760127          DOI： 10.6515/ACS.201909_35(5).20190906A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN： 1011-6842            Impact factor:   2.672


× No keyword cloud information.
  14 in total

Review 1.  2018 Expert Consensus on the Management of Adverse Effects of Antiplatelet Therapy for Acute Coronary Syndrome in Taiwan.

Authors:  Yi-Heng Li; Chih-Yuan Fang; I-Chang Hsieh; Wei-Chun Huang; Tsung-Hsien Lin; Shih-Hsien Sung; Chiung-Zuan Chiu; Chiung-Jen Wu; Kou-Gi Shyu; Po-Yuan Chang; Ching-Chang Fang; Tse-Min Lu; Ching-Pei Chen; Wei-Chen Tai; Chau-Chyun Sheu; Kai-Che Wei; Yi-Hsiu Huang; Hsing-Mei Wu; Juey-Jen Hwang Hwang
Journal:  Acta Cardiol Sin       Date:  2018-05       Impact factor: 2.672

2.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Authors:  Christopher P Cannon; Deepak L Bhatt; Jonas Oldgren; Gregory Y H Lip; Stephen G Ellis; Takeshi Kimura; Michael Maeng; Bela Merkely; Uwe Zeymer; Savion Gropper; Matias Nordaby; Eva Kleine; Ruth Harper; Jenny Manassie; James L Januzzi; Jurrien M Ten Berg; P Gabriel Steg; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

3.  Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: insights from the RealiseAF Taiwanese cohort.

Authors:  Kang-Ling Wang; Cheng-Hsueh Wu; Chin-Chou Huang; Tao-Cheng Wu; Lisa Naditch-Brûlé; Philippe Gabriel Steg; Shing-Jong Lin; Chern-En Chiang
Journal:  J Cardiol       Date:  2014-03-03       Impact factor: 3.159

4.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Authors:  Willem J M Dewilde; Tom Oirbans; Freek W A Verheugt; Johannes C Kelder; Bart J G L De Smet; Jean-Paul Herrman; Tom Adriaenssens; Mathias Vrolix; Antonius A C M Heestermans; Marije M Vis; Jan G P Tijsen; Arnoud W van 't Hof; Jurriën M ten Berg
Journal:  Lancet       Date:  2013-02-13       Impact factor: 79.321

Review 5.  The Management and Prognostic Factors of Acute Coronary Syndrome: Evidence from the Taiwan Acute Coronary Syndrome Full Spectrum Registry.

Authors:  Chun-Yuan Chu; Tsung-Hsien Lin; Wen-Ter Lai
Journal:  Acta Cardiol Sin       Date:  2017-07       Impact factor: 2.672

6.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

Authors:  S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf
Journal:  Lancet       Date:  2006-06-10       Impact factor: 79.321

7.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

8.  Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation.

Authors:  R D Lopes; K S Pieper; J R Horton; S M Al-Khatib; L K Newby; R H Mehta; F Van de Werf; P W Armstrong; K W Mahaffey; R A Harrington; E M Ohman; H D White; L Wallentin; C B Granger
Journal:  Heart       Date:  2008-03-10       Impact factor: 5.994

9.  Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.

Authors:  Pascal Vranckx; Marco Valgimigli; Lars Eckardt; Jan Tijssen; Thorsten Lewalter; Giuseppe Gargiulo; Valerii Batushkin; Gianluca Campo; Zoreslava Lysak; Igor Vakaliuk; Krzysztof Milewski; Petra Laeis; Paul-Egbert Reimitz; Rüdiger Smolnik; Wolfgang Zierhut; Andreas Goette
Journal:  Lancet       Date:  2019-09-03       Impact factor: 79.321

10.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

Authors:  C Michael Gibson; Roxana Mehran; Christoph Bode; Jonathan Halperin; Freek W Verheugt; Peter Wildgoose; Mary Birmingham; Juliana Ianus; Paul Burton; Martin van Eickels; Serge Korjian; Yazan Daaboul; Gregory Y H Lip; Marc Cohen; Steen Husted; Eric D Peterson; Keith A Fox
Journal:  N Engl J Med       Date:  2016-11-14       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.